Oppenheimer analyst Francois Brisebois reiterated a Buy rating on Durect (DRRX – Research Report) on March 27 and set a price target of $5.00.

In a report released on March 28, Francois Brisebois from Oppenheimer maintained a Buy rating on Sensei Biotherapeutics (SNSE – Research ...

Timothy Papp; Chief Financial Officer; DURECT Corp. James Brown; President, Chief Executive Officer, Director; DURECT Corp. Norman Sussman; Chief Medical Officer; DU ...

Operator: Greetings, and welcome to the DURECT Corporation Fourth Quarter and Full Year 2024 Earnings Conference Call. At ...

Discover DURECT's Q4 2024 earnings insights, progress on larsucosterol's Phase 3 trial for alcohol-associated hepatitis, and strategies to secure funding.

François Brisebois, Oppenheimer & Company: Asked about the estimated cost of the Phase 3 trial. CEO Brown stated it would be around $20 million, with potential for slight cost reductions.

Investing.com — Lundi, H.C. Wainwright a ajusté ses perspectives concernant Ovid Therapeutics Inc (NASDAQ:OVID), réduisant l’objectif de cours à 12 mois à 2,00$ contre 3,00$ précédemment. L’action, qu ...

Grâce à un contexte monétaire favorable et une dynamique soutenue de ses activités principales, le groupe vaudois enregistre ...

Investing.com — Lundi, l’analyste de BTIG Thomas Shrader a révisé l’objectif de cours d’ Ovid Therapeutics Inc (NASDAQ:OVID) à 4,00$, en baisse par rapport aux 5,00$ précédents, tout en maintenant une ...